Amyloid-Tau PET Fusion Reveals Covarying Network Territories Linked to Disease Stage, Cognition, and APOE4 in Alzheimers Disease
BackgroundAmyloid-beta (A{beta}) and Tau are defining pathologies of Alzheimers disease, but their relationship varies substantially across the brain. Amyloid deposition is spatially widespread, whereas Tau shows greater regional heterogeneity and closer relationships with disease severity. Consequently, understanding the disease requires more than measuring the two pathologies independently or summarizing them within predefined regions. A major unresolved question is how Amyloid and Tau covary across the whole brain, where their spatial patterns converge or diverge, and whether their local combination carries distinct information about disease stage and cognition. MethodsWe analyzed paired florbetapir Amyloid PET and flortaucipir Tau PET from the Alzheimers Disease Neuroimaging Initiative (ADNI), comprising 378 paired imaging sessions from 320 participants spanning cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimers Dementia (AD). High-order joint independent component analysis was used to identify fine-grained, data-driven patterns of Amyloid-Tau covariance across individuals. The resulting Amyloid and Tau maps were characterized by their spatial similarity and correspondence with rsfMRI-derived intrinsic functional networks. We then used the same data-driven spatial regions to quantify, for each participant, the relative extent of Amyloid abnormality alone, Tau abnormality alone, and spatially overlapping Amyloid-Tau abnormality. ResultsNinety-six non-artifactual Amyloid-Tau components were identified, of which 73 showed appreciable spatial correspondence between their paired Amyloid and Tau maps, while 17 were Tau-localized and 6 Amyloid-localized. Amyloid component maps more frequently corresponded with rsfMRI-derived intrinsic network organization than Tau maps. Expression of the joint components differed across diagnosis groups, demonstrating spatially heterogeneous disease-stage patterns. Within the same data-driven regions, isolated Amyloid, isolated Tau, and overlapping Amyloid-Tau abnormality showed markedly different disease-stage profiles: Amyloid-only abnormality was more prominent in the earlier CN-to-MCI contrast, Tau-only abnormality in contrasts involving AD, whereas spatially overlapping Amyloid-Tau abnormality showed the broadest differences across disease stages and the largest mean CN-to-AD expansion. Overlapping abnormality was also associated with cognition across the greatest number of components and showed the strongest overall association with ADAS13. APOE4-related diagnosis-stage differences were considerably more widespread for pathology measures containing Amyloid than for Tau-only abnormality.